New Stock News | Medical device company Maikerian passes Hong Kong Stock Exchange hearing, with three major business lines globally deployed and leading in multiple categories.

According to the Hong Kong Stock Exchange's disclosure on August 20, Shenzhen Micotian Biomedical Technology Co., Ltd. (referred to as Micotian) has passed the listing hearing on the main board of the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International acting as its joint sponsors. The prospectus shows that Micotian is a global provider of medical devices that meet clinical needs across a wide range of departments within medical institutions, including wards and clinics, as well as community health centers, testing institutions, and home care scenarios. As of March 31, 2026, the company's product portfolio includes over 60 life support products, 110 minimally invasive interventional products, and 150 in vitro diagnostic products, all available in various models to meet different application needs. Leveraging its innovative R&D platform, the company efficiently develops and upgrades products across its business units, ensuring that innovative products are inspired by real medical needs and effectively address those needs by translating clinical demands into innovative outcomes. During the track record period, the company strategically established five R&D centers and six production centers throughout China and the UK, creating competitive advantages in its respective medical fields and achieving significant accomplishments. Life Support. The company has developed a range of innovative life support products, including the world's first remote infusion control system, China's first independently developed multi-channel infusion workstation, an infusion workstation compatible with MRI environments, touch-screen infusion pumps, touch-screen syringe pumps, and touch-screen enteral nutrition pumps. By sales volume, it ranked first in the infusion workstation market in China from 2018 to 2025 and also ranked first in the enteral nutrition pump market in China from 2021 to 2025. Minimally Invasive Interventions. The company is one of the few domestic brands in China that has proprietary endoscopic product offerings, including reusable and disposable endoscopic systems and related consumables. By sales volume, it ranked among the top three in the Chinese market for minimally invasive intervention consumables for the digestive system from 2022 to 2025 and was ranked among the top five in the disposable choledochoscope market in China from 2023 to 2025. In Vitro Diagnostics. The company launched the worlds first fully automated thromboelastography analyzer in 2021. By sales volume, it is expected to rank among the top five in the Chinese blood typing device market by 2025. Thanks to its solid capabilities, the companys products have reached over 140 countries and regions worldwide. In China, its products have been used in over 6,000 hospitals, covering approximately 90% of Class III Grade A hospitals, across 31 provinces, municipalities, and autonomous regions. Internationally, the company has established a business presence globally, with its medical products available throughout the Asia-Pacific, Europe, the Middle East, Africa, and the Americas. Furthermore, to enhance its international service capabilities, the company has local representative offices in strategic markets such as the UK, the Netherlands, Belgium, Turkey, India, Thailand, Indonesia, Mexico, Brazil, and Colombia, ensuring timely and localized support for its global customer base. With a strong global distribution network and regional service teams, the company provides reliable sales and after-sales support across multiple time zones. In terms of finance, for the fiscal years 2023, 2024, 2025, and the three months ended March 31, 2026, the company achieved total revenues of approximately RMB 1.313 billion, RMB 1.399 billion, RMB 1.619 billion, and RMB 422 million, respectively.